Skip to content

Neuromodulation of Lidocaine Cream Effect on Chronic Pain Patients

Neuromodulation of Lidocaine Cream Effect on Chronic Pain Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03046017
Enrollment
90
Registered
2017-02-08
Start date
2017-08-30
Completion date
2023-05-31
Last updated
2023-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Brief summary

Chronic low back pain patients aged 21 to 60 needed for a research study of the effects of transcranial direct current stimulation (tDCS) on the analgesic effects of lidocaine cream as measured by functional Magnetic Resonance Imaging (fMRI). Study will be conducted on nine separate days not requiring an overnight stay in the hospital.

Interventions

DEVICEtDCS

Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.

Lidocaine cream will be applied to reduce pain sensitivity (analgesia).

A neutral cream will be applied as a control.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Volunteers 21-60 years of age. * Meets the Classification Criteria of chronic LBP (having low back pain for more than 6 months), as determined by the referring physician. * At least 4/10 clinical pain on the 11-point LBP VAS (criteria recommended by Dworkin et al.) * At least a 10th grade English-reading level; English can be a second language provided that the patients understand all questions used in the assessment measures.

Exclusion criteria

* Specific causes of back pain (e.g., cancer, fractures, spinal stenosis, infections). * Complicated back problems (e.g., prior back surgery, medicolegal issues). * The intent to undergo surgery during the time of involvement in the study. * History of cardiac, respiratory, or nervous system disease that, in the investigator's judgment, precludes participation in the study because of a heightened potential for adverse outcome. For example: asthma, claustrophobia, epilepsy or acute eczema under the electrodes. * Presence of any contraindications to MRI scanning. For example: cardiac pacemaker, metal implants, claustrophobia, pregnancy, cannot lie still in an fMRI scanner. * History of medical or psychiatric illness. * History of substance / alcohol abuse or dependence.

Design outcomes

Primary

MeasureTime frame
fMRI signal changes2 days; Sessions 5 and 7
Gracely Scale pain rating changes2 days; Sessions 2 and 7
resting state functional connectivity changes2 days; Sessions 5 and 7

Countries

United States

Contacts

Primary ContactGeorgia Wilson, BA
gjwilson@mgh.harvard.edu617-726-5004

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026